G&S Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

G&S Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-562	Closed	-$405K	–	122
2022 Q4	$405K	Buy	+562	New	+$415K	0.18%	91
2020 Q4	–	Sell	-595	Closed	-$333K	–	101
2020 Q3	$333K	Buy	595 +100	+20%	+$60.6K	0.24%	73
2020 Q2	$309K	Sell	495 -116	-19%	-$65.8K	0.28%	55
2020 Q1	$298K	Buy	+611	New	+$252K	0.52%	36

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

G&S Capital's REGN Position: Q1 2023 in Review

G&S Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 562 shares — an estimated $405K sold.

G&S Capital first reported a position in REGN in Q1 2020 and held it in 4 quarters. The position peaked at $405K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

G&S Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
G&S Capital sold 562 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $405K.
G&S Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 4 quarters.
G&S Capital's Regeneron Pharmaceuticals position peaked at $405K in Q4 2022.
1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on G&S Capital's 13F filing for Q1 2023, filed 21 Apr 2023.